Streetbeat News

Stock Prices

ZS

Zscaler shares are experiencing a decline in trading following the release of their Q4 earnings report.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 8:09 pm

PD

PagerDuty reported a Q2 2025 adjusted EPS of $(0.14), missing the analyst estimate of $0.17. Sales were $115.90M, slightly below the $116.48M estimate, but up 7.70% from last year.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 8:08 pm

GTLB

GitLab reported Q2 2025 earnings of $0.15 per share, surpassing the $0.10 estimate, and sales of $182.6M, exceeding the $176.889M estimate. This marks a 30.82% increase in sales from the previous year.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 8:07 pm

VATE

INNOVATE Corp. has received a compliance notice from the NYSE, indicating that it has regained compliance with the exchange's minimum price requirement. This development is crucial for the company to maintain its listing on the NYSE.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 8:07 pm

ZS

Zscaler reported strong Q4 2024 results, with adjusted EPS of $0.88 beating estimates by 27.54% and sales of $592.9M surpassing expectations by 4.40%. This marks a 30.31% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 8:06 pm

CRBU

Caribou Biosciences' CFO, Jason O'Byrne, has announced his intent to resign as of September 1. This leadership change could impact the company's financial strategy and investor confidence.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 8:04 pm

HQY

HealthEquity reported strong Q2 2025 results, with adjusted EPS of $0.86 beating estimates by 22.86% and sales of $299.928M surpassing expectations by 5.29%. This marks a 23.15% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 8:04 pm

PCVX

Vaxcyte has announced a proposed public offering of $1 billion in common stock and pre-funded warrants. This move is likely aimed at raising capital for the company's operations and development projects.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 8:03 pm

ATHA

Athira Pharma announced that its Phase 2/3 LIFT-AD clinical trial for Fosgonimeton, aimed at treating mild-to-moderate Alzheimer's disease, did not meet its primary and key secondary endpoints. This could impact investor sentiment negatively.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 8:02 pm

COIN

DIS

MCD

NVDA

Nvidia's stock has seen a significant decline since its Q2 earnings report, losing $413.1 billion in market capitalization, more than the combined value of McDonald's, Disney, and Coinbase. Despite beating earnings and revenue estimates, the stock fell due to concerns over slowing growth rates and margins. Analysts have mixed views, with some seeing the dip as a buying opportunity. Nvidia's stock is still up 126% year-to-date.

Portfolio Pulse from Chris Katje

September 03, 2024 | 8:01 pm